Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Pharmaceutical TechnologyNew data presented at ACC 2026 clarifies sotatercept's role alongside vasodilator-based regimens in PAH patients.Clinical DataCardiovascularRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients. Clinical DataCardiovascularRead full story Post navigation Previous: Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is ChillingNext: Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
